Stock GNPX GENPREX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Genprex, Inc.

Equities

GNPX

US3724462037

Delayed Nasdaq
Other stock markets
 01:30:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
1.91 USD -3.05% Intraday chart for Genprex, Inc. -2.55% -79.24%
May. 15 Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 14 Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
AQ
Genprex : 2024 Genprex Stockholder Letter
PU
Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
CI
Genprex, Inc. Appoints Jose A. Moreno Toscano as Chairman of the Board of Directors
CI
Genprex, Inc Announces Executive Changes
CI
Genprex, Inc Announces Executive Changes
CI
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
AQ
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System
AQ
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
CI
Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
CI
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target
MT
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants
MT
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
AQ
Genprex Launches $6.5 Million Securities Offering; Shares Fall
MT
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
AQ
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
MT
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
CI
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNPX Stock
  4. News Genprex, Inc.